• December 7, 2024 – New Suboxone Lawsuit

    Published On: December 29, 2024|Categories: Suboxone|By |

    A new lawsuit has been filed by a plaintiff from Madison, Indiana, who claims that the makers of Suboxone failed to warn users about the drug’s severe dental damage risks. The lawsuit alleges that Indivior and Aquestive Therapeutics knew about these risks for over a decade but didn’t provide proper warnings. Despite a 2022 FDA alert confirming the dental issues linked to buprenorphine products dissolved in the mouth, the plaintiff argues that the medication guides were never updated adequately.

  • November 25, 2024: Changes to Case Management Order #3

    Published On: December 29, 2024|Categories: Suboxone|By |

    On Friday, Judge Calabrese made changes to Case Management Order No. 3, which allows plaintiffs claiming dental injuries from Suboxone film to file their cases directly in his Ohio court. The update specifically addresses how legal documents are delivered. Defendants, including Indivior Inc., Indivior Solutions Inc., and Aquestive Therapeutics, have agreed to waive the formal process of serving summons for cases within the MDL.

  • November 11, 2024: Pill vs. Film

    Published On: December 29, 2024|Categories: Suboxone|By |

    We often receive calls from people who took the Suboxone pill and want to file a claim. It’s frustrating when we can’t assist them, and we understand that. However, the key to these claims lies in the sublingual film version.

    The film dissolves in the mouth before being absorbed, leading to prolonged exposure to the drug. This extended contact affects the mouth’s pH balance. Buprenorphine and naloxone in the film lower the mouth’s natural pH, which can cause harm. Suboxone lawyers argue that the manufacturers failed to warn about these risks and that the film form is more harmful than previous versions of the drug.

  • October 18, 2024 – Suboxone Overdose

    Published On: December 29, 2024|Categories: Suboxone|By |

    As we continue with the Suboxone litigation, we’ve learned a lot more about the drug. Initially, we considered whether Suboxone should be recalled after seeing the severe dental damage it caused.

    However, we now recognize the benefits of Suboxone, such as its low overdose risk and long-term manageability when side effects are controlled. Instead of supporting a recall, we believe there should be a strong warning (which still doesn’t exist in 2024) to help people make informed decisions and manage the risks of severe tooth decay.